Clinical Trial Update: CX-4945 in Viral Community Acquired Pneumonia [Phase 2]

View source ↗

Summary

A Phase 2 trial of CX-4945 for viral community-acquired pneumonia, including COVID-19 pneumonia and influenza with pneumonia, was terminated and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Community-acquired Pneumonia
• Influenza with Pneumonia

Drugs mentioned

• CX-4945 (silmitasertib)

Snippet

Sponsor: Senhwa Biosciences, Inc. | Conditions: Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Status: TERMINATED | Results posted: 2026-01-08